FindTrial
Sign In

Prediction of therapeutic effect and prognosis of different treatment schemes for idiopathic membranous nephropathy by intestinal flora

Prediction of therapeutic effect and prognosis of different treatment schemes for idiopathic membranous nephropathy by intestinal flora

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050205
Enrollment
Unknown
Registered
2021-08-22
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy

Interventions

control group:Nil
experimental group 1:Symptomatic treatment
experimental group 2:Hormone+Tacrolimus
experimental group 3:Hormone+Cyclophosphamide
experimental group 4:Hormone+Mycophenolate mofetil ester
experimental group 5:Rituximab

Sponsors

The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. After renal biopsy, the patient was pathologically diagnosed as IMN.

Exclusion criteria

Exclusion criteria: 1. Secondary IMN (caused by infection, tumor, autoimmune disease, etc.).

Design outcomes

Primary

MeasureTime frame
24-hour urine total protein;serum albumin;serum creatinine;phospholipase A2 receptor;eGFR;Changes of intestinal flora;—

Countries

China

Contacts

Public ContactWang Zunsong

Shandong First Medical University

wzsong3@163.com+86 15966608835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026